What type of delivery system does Ranibizumab (Susvimo) utilize?

Ranibizumab (Susvimo) utilizes an implanted port system, which is designed to provide sustained delivery of the medication directly to the eye. This delivery method allows for long-term treatment in patients with conditions like age-related macular degeneration (AMD) and other causes of choroidal neovascularization (CNV). The system helps maintain therapeutic drug levels with less frequent dosing compared to traditional intravitreal injections, which can be more invasive and less convenient for patients.

The implanted port system specifically caters to the need for prolonged localized treatment, minimizing the risk of systemic side effects and reducing the burden of frequent clinic visits for injections. This innovative approach represents a significant advancement in the management of retinal diseases, emphasizing patient comfort and treatment adherence.